Rosene et al v. GlaxoSmithKline, LLC
| Rosene Lydia, Rosene Jonathan, Jonathan Rosene and Lydia Rosene |
| GlaxoSmithKline, LLC |
| 1:2018cv12259 |
| October 30, 2018 |
| US District Court for the District of Massachusetts |
| F Dennis Saylor |
| Personal Inj. Prod. Liability |
| 28 U.S.C. ยง 1332 |
| Plaintiff |
Docket Report
RSS Track this Docket
This docket was last retrieved on November 14, 2018. A more recent docket listing may be available from PACER.
| Document Text |
|---|
| Filing 7 Electronic Clerk's Notes for proceedings held before Judge F. Dennis Saylor, IV: Status Conference held on 11/14/2018.(1) The Court heard updates on the current total of federal and state filings.(2) The Court heard updates on pending state court cases. The Court requested contact information for the judge presiding over the Oregon state court case. (3) The Court heard updates on expert discovery. The Court approved of the proposed Daubert briefing schedule, as set forth in Joint Motion for Entry of Supplement to MDL Order No. 25 (Docket No. 1207), and set hearing dates of March 5, 2019, for general causation experts, and March 14, 2019, for regulatory experts. (4) The Court heard updates on general and case-specific fact discovery, including GSK's forthcoming Motion for Entry of Order Governing Depositions of Healthcare Provider Fact Witnesses. At the parties' request, the Court extended the Group 1 discovery deadline to February 8, 2019, and the Group 2 discovery deadline to April 11, 2019. (5) The Court set a tentative trial date of June 3, 2019. The parties expect the trial to last approximately three weeks. (6) The Court heard argument on Plaintiffs' Motion for Dismissal Without Prejudice to the Rights of G.K. to Bring a Future Claim (Kutzer v. GSK, Case No. 1:15-cv-13751, Docket No. 88) and took the matter under advisement. (7) The Court set the following status conference dates for 2019: March 5, 2019; April 8, 2019; and May 8, 2019. (Court Reporter: Valerie OHara at vaohara@gmail.com.)(Attorneys present: Various) Associated Cases: 1:15-md-02657-FDS et al.(Pezzarossi, Lisa) |
| Filing 6 NOTICE RE: 11/14/2018 STATUS CONFERENCE scheduled to begin at 1:30 PM: Parties participating in the status conference must use the following DIAL-IN INSTRUCTIONS: (1) the participant dial-in number is 877-876-9174 and (2) Conference ID: ZOFRAN. The operator will ask for the Conference ID when dialing in. The phone line is open at 1:15 pm. Associated Cases: 1:15-md-02657-FDS et al.(Pezzarossi, Lisa) |
| Filing 5 NOTICE of Appearance by Jennifer M. Stevenson on behalf of GlaxoSmithKline, LLC (Stevenson, Jennifer) |
| Filing 4 Summons Issued as to GlaxoSmithKline, LLC. Counsel receiving this notice electronically should download this summons, complete one for each defendant and serve it in accordance with Fed.R.Civ.P. 4 and LR 4.1. Summons will be mailed to plaintiff(s) not receiving notice electronically for completion of service. (McDonagh, Christina) |
| Filing 3 NOTICE OF MDL CASE OPENED, Direct file in the District of Massachusetts; Rosene, et al v. GlaxoSmihKline, LLC. In Re: Zofran (Ondansetron) Products Liability Litigation, MDL 2657. (Finn, Mary) |
| Filing 2 ELECTRONIC NOTICE of Case Assignment. Judge F. Dennis Saylor, IV assigned to case. (Finn, Mary) |
| Filing 1 COMPLAINT Short Form against GlaxoSmithKline, LLC Filing fee: $ 400, receipt number 0101-7387421 (Fee Status: Filing Fee paid), filed by Jonathan Rosene , Lydia Rosene. (Attachments: #1 Civil Cover Sheet, #2 Exhibit)(Fleishman, Wendy) |
Access additional case information on PACER
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Massachusetts District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
